The coveted cat keychain is part of a collaboration between KFC and Mofusand, a popular Japanese cat illustration series, which released limited stocks of the trinkets, as well as sticker packs ...

A ~$4.5B share repurchase program adds further value. LIBTAYO demonstrated massive growth, accelerating to 50% in Q4 2024 versus Q4 2023. Approval in CSCC means that this growth catalyst is ...

In the fourth quarter of 2024, Libtayo grew sales 50% to $367 million, propelling the PD-1 treatment past the blockbuster threshold for the first time. During the full year, the drug's sales reach ...

That's what makes the tiny new Ysmart Bullet2 a great choice out in the wilderness: it's small enough to fit on a keychain or belt loop, and it turns on as soon as you yank it from its magnetic base.

When the first batch of merchandise — comprising cat plushie keychains donning KFC bucket hats — was released on Monday (Jan 13), these were snapped up in a few hours. Within the day ...

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...

Sales for the first item – a cat keychain with a KFC bucket on its head – started on Jan 13, with two new designs to be released each week. Already, scalpers are reselling the first wave of ...

The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell ...

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...